Literature DB >> 34838524

Incidental Findings on Low-Dose CT Scan Lung Cancer Screenings and Deaths From Respiratory Diseases.

Paul F Pinsky1, David A Lynch2, David S Gierada3.   

Abstract

BACKGROUND: Incidental respiratory disease-related findings are frequently observed on low-dose CT (LDCT) lung cancer screenings. This study analyzed data from the National Lung Screening Trial (NLST) to assess the relationship between such findings and respiratory disease mortality (RDM), excluding lung cancer. RESEARCH QUESTION: Are incidental respiratory findings on LDCT scanning associated with increased RDM? STUDY DESIGN AND METHODS: Subjects in the NLST LDCT arm received three annual screens. Trial radiologists noted findings related to possible lung cancer, as well as respiratory-related incidental findings. Demographic characteristics, smoking history, and medical history were captured in a baseline questionnaire. Kaplan-Meier curves were used to assess cumulative RDM. Multivariate proportional hazards models were used to assess risk factors for RDM; in addition to incidental CT scan findings, variables included respiratory disease history (COPD/emphysema, and asthma), smoking history, and demographic factors (age, race, sex, and BMI).
RESULTS: Of 26,722 subjects in the NLST LDCT arm, 25,002 received the baseline screen and a subsequent LDCT screen. Overall, 59% were male, 26.5% were aged ≥ 65 years at baseline, and 10.6% reported a history of COPD/emphysema. Emphysema on LDCT scanning was reported in 30.7% of subjects at baseline and in 44.2% at any screen. Of those with emphysema on baseline LDCT scanning, 18% reported a history of COPD/emphysema. Median mortality follow-up was 10.3 years. There were 3,639 deaths, and 708 were from respiratory diseases. Among subjects with no history of COPD/emphysema, 10-year cumulative RDM ranged from 3.9% for subjects with emphysema and reticular opacities to 1.1% for those with neither condition; the corresponding range among subjects with a COPD/emphysema history was 17.3% (both) to 3.7% (neither). Emphysema on LDCT imaging was associated with a significantly elevated RDM hazard ratio (2.27; 95% CI, 1.92-2.7) in the multivariate model. Reticular opacities (including honeycombing/fibrosis/scar) also had a significantly elevated hazard ratio (1.39; 95% CI, 1.19-1.62).
INTERPRETATION: Incidental respiratory disease-related findings observed on NLST LDCT screens were frequent and associated with increased mortality from respiratory diseases.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  emphysema; incidental findings; low-dose CT; respiratory disease; screening

Mesh:

Year:  2021        PMID: 34838524      PMCID: PMC9005861          DOI: 10.1016/j.chest.2021.11.015

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   10.262


  23 in total

1.  The National Lung Screening Trial: overview and study design.

Authors:  Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak
Journal:  Radiology       Date:  2010-11-02       Impact factor: 11.105

Review 2.  Incidental Findings on Lung Cancer Screening: Significance and Management.

Authors:  Emily B Tsai; Caroline Chiles; Brett W Carter; Myrna C B Godoy; Girish S Shroff; Reginald F Munden; Mylene T Truong; Carol C Wu
Journal:  Semin Ultrasound CT MR       Date:  2018-03-01       Impact factor: 1.875

3.  Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial.

Authors:  Esther Pompe; Pim A de Jong; David A Lynch; Nikolas Lessmann; Ivana Išgum; Bram van Ginneken; Jan-Willem J Lammers; Firdaus A A Mohamed Hoesein
Journal:  Eur Respir J       Date:  2017-04-19       Impact factor: 16.671

4.  Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Authors:  Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

5.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

6.  Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial.

Authors: 
Journal:  J Thorac Oncol       Date:  2019-06-28       Impact factor: 15.609

Review 7.  Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation.

Authors:  Linda L Humphrey; Mark Deffebach; Miranda Pappas; Christina Baumann; Kathryn Artis; Jennifer Priest Mitchell; Bernadette Zakher; Rongwei Fu; Christopher G Slatore
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

8.  Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality.

Authors:  Tomoyuki Hida; Mizuki Nishino; Takuya Hino; Junwei Lu; Rachel K Putman; Elias F Gudmundsson; Tetsuro Araki; Vladimir I Valtchinov; Osamu Honda; Masahiro Yanagawa; Yoshitake Yamada; Akinori Hata; Masahiro Jinzaki; Noriyuki Tomiyama; Hiroshi Honda; Raul San Jose Estepar; George R Washko; Takeshi Johkoh; David C Christiani; David A Lynch; Vilmundur Gudnason; Gunnar Gudmundsson; Gary M Hunninghake; Hiroto Hatabu
Journal:  Eur J Radiol       Date:  2020-05-18       Impact factor: 3.528

9.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

10.  Impact of a Medical Diagnosis on Decision to Stop Smoking and Successful Smoking Cessation.

Authors:  Hunter G Lindsay; Frederick S Wamboldt; Kristen E Holm; Barry J Make; John Hokanson; James D Crapo; Elizabeth A Regan
Journal:  Chronic Obstr Pulm Dis       Date:  2021-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.